Gabapentin Aurobindo

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gabapentin Aurobindo

Property Description
Active Ingredient Gabapentin
Pharmacological Class Anticonvulsant / Anti-epileptic Agent
Form Capsules, Tablets, Oral Solution
Origin Synthetic Compound
Therapeutic Role Stabilization of neuronal excitability

What Type of Medicine is Gabapentin Aurobindo?

Gabapentin Aurobindo is a prescription medication chemically classified as an anticonvulsant and anti-epileptic agent. It is a generic product containing the single active substance, Gabapentin, and belongs to the class of medicines known as gabapentinoids. Anticonvulsants are used to control abnormal electrical activity in the central nervous system.

The drug entity is defined by the core action of its active ingredient. As a generic formulation produced by Aurobindo Pharma USA, it provides a therapeutically equivalent alternative to the original reference product, a factor contributing to expanded patient access to essential treatments. This classification places it among agents specifically designed to modulate electrical signaling in the brain and thus stabilize overactive nerve function.


Composition, Form, and Chemical Origin

The medicine’s composition centers exclusively on the active ingredient Gabapentin (C9H17NO2), a chemically synthesized solid and a structural analogue of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA). Gabapentin Aurobindo is manufactured for oral administration in several formats, including hard capsules, tablets, and an oral solution.

Unlike other GABA-related compounds, Gabapentin does not primarily bind to GABA receptors. Its therapeutic effects are largely achieved by binding to the alpha2delta-1 subunit of voltage-gated calcium channels. This synthetic compound is a single-ingredient product, formulated with necessary excipients for its chosen dosage form, and is typically used to help relieve the persistent shooting pain characteristic of neuropathic conditions by stabilizing nerve signaling.

Regulatory References

  1. Gabapentin: MedlinePlus Drug Information

What side effects are possible with Gabapentin Aurobindo?

Official Safety Profile and Adverse Reactions

The safety profile of Gabapentin, the active ingredient in this medicine, is officially documented by government regulatory agencies (such as the FDA and EMA) through specific frequency classifications and System-Organ-Class groupings. The medicine is primarily associated with effects on the Nervous System.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized based on their rate of occurrence as observed in clinical studies:

Frequency Classification Examples of Officially Documented Reactions
Very Common (occurs in 1 in 10 people) Dizziness, Somnolence (Drowsiness), Ataxia (Impaired Coordination), Fatigue.
Common (occurs in 1 to 10 in 100 people) Weight Gain, Tremor, Dysarthria (Speech Disorder), Nausea, Vomiting, Viral Infection.

Serious Safety Considerations

Official regulatory documents mandate warnings regarding serious and rare risks. These include the potential for Severe Cutaneous Adverse Reactions (SCARs), such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), and Anaphylaxis.

Like other anti-epileptic agents, the medicine is associated with an increased regulatory risk warning regarding Suicidal Ideation and Behavior.

Population-Specific Notes and Safety Constraints

Regulatory information requires specific attention for certain groups. Dose adjustments are necessary for patients with Renal Impairment due to how the medicine is cleared from the body. Some effects, such as dizziness and somnolence, are officially noted as being more frequent at the start of treatment or during dose increases. Abrupt discontinuation, particularly in patients with epilepsy, carries an official risk of withdrawal seizures.

Overdose and Emergency Response

The official regulatory documents describe Gabapentin overdose primarily through a profile of central nervous system (CNS) depression. Documented clinical manifestations reported in cases of acute oral overdose include drowsiness, lethargy, slurred speech (dysarthria), and double vision (diplopia). Gastrointestinal effects such as diarrhea have also been reported as part of the overdose presentation.

Overdose may escalate to severe outcomes, including loss of consciousness, coma, and respiratory depression, particularly following high-dose ingestion or in patients with pre-existing conditions. Regulatory information explicitly notes that the severity of toxicity is often increased for individuals with impaired renal function due to the drug's significantly reduced clearance by the kidneys.

Upon any suspected overdose, individuals must seek immediate medical attention and contact a Poison Control Center, as mandated by official labeling. There is no specific antidote known for Gabapentin overdose. Management is officially directed toward providing symptomatic and supportive treatment and requires hospital monitoring. In cases of severe clinical toxicity, the regulatory profile notes that hemodialysis may be indicated as a supportive procedure to help remove the drug from the body.

Therapeutic Uses of Gabapentin Aurobindo

This medication is commonly used across two primary therapeutic domains.

Relief from Chronic Neuropathic Pain

This medication is primarily used to address the symptoms related to physical discomfort associated with neuropathic pain conditions. It targets the characteristic symptomatic cluster of shooting, burning, and stabbing sensations that arise from nerve damage, providing supportive relief that generally helps ease the overall symptom burden. Gabapentin is specifically applied in clinical settings that involve conditions such as Postherpetic Neuralgia (PHN) and as an add-on therapy for partial-onset seizures in adults and pediatric patients 3 years of age.

“The therapeutic goal is to help patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort.”

Stabilization of Nerve Hyperexcitability

The therapeutic role of this medication is to provide support for conditions marked by increased physiological stress and symptoms related to heightened neurological activity, which are associated with both the persistent pain signals and the uncontrolled electrical bursts of seizures. By helping to stabilize these hyperexcitable nerve pathways, the medicine offers a supportive therapeutic benefit that contributes to improved comfort and assists with maintaining functional stability in relevant clinical settings.


Quick Fact: Relief for Neuropathic Symptoms The medication is commonly used to help manage the symptoms related to intense, persistent burning, shooting, and stabbing nerve pain often associated with Postherpetic Neuralgia, offering symptomatic assistance during periods of heightened discomfort.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Gabapentin Aurobindo — Official Regulatory Information

Gabapentin Aurobindo's eligibility is determined by official regulatory criteria, primarily related to age, physiological status, and contraindication history.

Eligibility Status Applicable Population or Condition
Absolutely Contraindicated Patients with a known hypersensitivity (allergic reaction) to gabapentin or any component of the product, or a prior history of a severe reaction (e.g., DRESS, SJS) to the drug.
Approved for Use Adults for Postherpetic Neuralgia and Partial-Onset Seizures. Pediatric patients 3 years and older for Adjunctive Therapy for Partial-Onset Seizures.
Use Not Established Children under 3 years of age for any approved indication; use for Postherpetic Neuralgia in any pediatric patient (under 18 years).
Conditional Use (Restriction) Patients with Renal Impairment (including older adults) require close medical oversight, as the medicine's clearance is directly proportional to kidney function. Patients undergoing Hemodialysis require specific supplemental dosing protocols.
Pregnancy and Lactation Use during pregnancy is generally advised only if the potential benefit justifies the potential risk to the fetus due to limited human data. Gabapentin is secreted into human milk, necessitating a careful risk-benefit assessment while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines officially documented interaction patterns based strictly on government regulatory labeling. No strictly contraindicated combinations are listed based on interaction risk alone.

Interaction Type Interacting Substance/Class Official Regulatory Statement
Pharmacodynamic CNS Depressants (including Opioids, Alcohol) Co-administration increases the risk of additive CNS depression, leading to potential somnolence, dizziness, and severe respiratory depression.
Pharmacokinetic (Absorption) Antacids (containing Aluminum/Magnesium) Co-administration decreases the bioavailability (absorption) of Gabapentin, resulting in reduced plasma exposure.
Pharmacokinetic (Excretion) Cimetidine, Morphine Co-administration has been shown to reduce the renal clearance of Gabapentin, which can lead to minor increases in its concentration.
Metabolic CYP450 System Gabapentin is not appreciably metabolized and does not induce hepatic enzymes; therefore, it is not expected to interact via this metabolic pathway.

Timing-Based Administration Restriction

To avoid a reduction in Gabapentin exposure, administration must be separated. Gabapentin should be taken at least two hours following administration of an antacid containing aluminum and/or magnesium.

Population-Specific Cautions

Since clearance is dependent on renal function, the elderly and patients with renal impairment have a higher risk of adverse effects, particularly when combining Gabapentin with other CNS depressants, due to potentially reduced drug clearance.

Mechanism of Action

How Gabapentin Aurobindo Works

Gabapentin functions primarily as a ligand that acts centrally on the nervous system. The drug's mechanism is initiated by binding with high affinity to the alpha2delta-1 subunit of presynaptic voltage-gated calcium channels (VGCCs). This molecular interaction is the foundational step that distinguishes its pharmacodynamics.

The binding modulates the calcium channel complex's function by inhibiting the forward trafficking and insertion of the channels into the nerve terminal membrane. This reduction in functional VGCC density consequently limits the influx of calcium ions upon neuronal depolarization.

By restricting the presynaptic calcium current, the drug directly attenuates the release of excitatory neurotransmitters, notably Glutamate, from the nerve terminal. This cascade reduces the chemical communication that drives signal amplification in specific neural circuits, resulting in the modulation of activity within key pathways, including the Spinal Cord Dorsal Horn. The overall physiological effect is a change in the frequency of neuronal firing patterns, influencing overall nervous system activity.

Dosage and Administration Information

How to use Gabapentin Aurobindo — Official Administration Guidelines

Gabapentin is for oral administration and must be taken exactly as prescribed. The capsules and tablets should be swallowed whole with water and can be taken with or without food.

Official Dosing Rules and Frequency

Gabapentin is typically administered in three divided doses throughout the day (T.I.D.). For patients taking the medication for seizures, the maximum time interval between any two doses must not exceed 12 hours to help prevent breakthrough seizures.

Patient Group Starting Dose (Typical) Maintenance Dose (Typical) Maximum Dose
Adults (for Seizures) 300 mg T.I.D. 300 mg to 600 mg T.I.D. Up to 3600 mg/day (in three divided doses)
Pediatrics (Ages 5-11) 10 to 15 mg/kg/day (T.I.D.) 25 to 35 mg/kg/day (T.I.D.) Up to 50 mg/kg/day

Procedural and Administration Conditions

  • Preparation: Capsules must be swallowed whole. Scored tablets may be broken, but the unused half-tablet should be taken as the next scheduled dose.
  • Antacids: If you are taking an antacid containing aluminum or magnesium, take Gabapentin at least 2 hours after the antacid to avoid reducing the drug's absorption.
  • Missed Dose: If a dose is missed, take it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and continue the regular dosing schedule; do not double the dose.
  • Renal Impairment: Dosing must be adjusted for patients with reduced kidney function (creatinine clearance <80 mL/min) according to the prescriber's guidelines.
  • Discontinuation: If treatment must be reduced, stopped, or substituted, it should be done gradually over a minimum of one week to prevent the occurrence of seizures.

Recent Clinical Evidence

Research Summary

Gabapentin is structurally similar to the inhibitory neurotransmitter GABA, but its action is not mediated through GABA receptors. Research suggests its primary proposed mechanism involves binding to the alpha-2-delta (alpha2delta) subunit of voltage-gated calcium channels. This interaction is thought to result in the reduction of excitatory neurotransmitter release in the central nervous system.

Studies have evaluated gabapentin for use as an adjunctive therapy for partial seizures and for the management of peripheral neuropathic pain, such as painful diabetic neuropathy and postherpetic neuralgia (PHN).

Key Study Findings

Peripheral Neuropathic Pain

Randomized controlled trials (RCTs) have compared gabapentin to placebo in adults with PHN and painful diabetic neuropathy. These studies primarily assessed changes in pain severity using standardized scales (e.g., the 11-point Likert scale).

  • Postherpetic Neuralgia: In PHN trials, a greater proportion of participants receiving gabapentin reported a reduction in pain severity compared to those receiving placebo. Research also examined secondary outcomes, which included improvements in sleep interference and some measures of quality of life.
  • Epilepsy (Partial Seizures): Studies supporting the use of gabapentin as an add-on therapy for partial-onset seizures focused on measuring the frequency of seizures compared to baseline, with evidence gathered in adults and adolescents aged 12 years and above.

Adverse Event and Tolerability Data

Adverse events reported most often in clinical research across various indications included dizziness, somnolence (drowsiness), and peripheral edema (swelling of the hands or feet). In some analyses, the incidence of peripheral edema was reported to increase at daily dosages of 1800, mg or greater. Clinicians are advised to monitor for rare but serious adverse reactions, including DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) and anaphylaxis, as reported in post-marketing surveillance.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline: Neuropathic pain in adults: pharmacological management in non-specialist settings

Frequently Asked Questions (FAQ)

Common questions about Gabapentin Aurobindo (FAQ)

Q: Is Gabapentin Aurobindo a generic drug?

Gabapentin Aurobindo is a generic product containing the active ingredient gabapentin. Official product information identifies the original brand-name version of this medicine as Neurontin. As a generic, it is described as a therapeutically equivalent alternative to the reference product.


Q: How long does the effect of one dose of Gabapentin Aurobindo generally last?

Pharmacokinetic data in the official prescribing information describes the average elimination half-life of gabapentin in adults with normal kidney function as approximately 5 to 7 hours. This value reflects the time it takes for half of the medicine to be cleared from the body. This characteristic helps explain why a healthcare provider often prescribes the drug to be administered multiple times throughout the day.


Q: Is it common to feel tired or dizzy after starting Gabapentin Aurobindo?

Yes, dizziness and tiredness, also known as somnolence, are officially classified as very common adverse reactions. Regulatory information notes that these central nervous system effects are often reported to be more frequent when treatment is first started or when the dose is increased.


Q: Is there a risk of dependence or withdrawal with Gabapentin Aurobindo?

Official post-marketing surveillance reports have associated the use of gabapentin with instances of abuse and dependence. Furthermore, regulatory warnings note that stopping the medicine abruptly, especially in patients taking it for seizures, carries a risk of withdrawal seizures. If treatment must be stopped or reduced, official guidance states it should be done gradually to help prevent adverse events.


Q: Is it true that Gabapentin Aurobindo can cause weight change?

Weight gain is listed as a common adverse reaction in the official safety profile. Another common side effect is peripheral edema (swelling of the hands or feet), which may contribute to an increase in body weight.


Q: What should I know about combining Gabapentin Aurobindo with alcohol?

Official guidance warns about the risks of combining this medicine with alcohol. Alcohol is classified as a central nervous system (CNS) depressant, and combining it with gabapentin can increase the risk of severe side effects such as excessive drowsiness, dizziness, and respiratory depression (slowed or shallow breathing).


Q: Is Gabapentin Aurobindo related to opioids in any way?

Gabapentin is not chemically related to opioids and does not act on opioid receptors in the brain. However, regulatory documents highlight the interaction risk when they are taken together. Co-administration with opioids is associated with an increased risk of severe effects, including respiratory depression and deep sedation.


Q: What kind of studies have been done on the safety of Gabapentin Aurobindo?

Safety data is gathered through both controlled clinical trials and mandatory post-marketing surveillance. Clinical trials categorize adverse reactions by frequency, while post-marketing surveillance monitors for rare but serious safety concerns, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and suicidal ideation.


Q: What is the main reason doctors prescribe Gabapentin Aurobindo?

Gabapentin is approved by regulatory agencies for specific uses. These include acting as an add-on therapy for treating partial-onset seizures and managing Postherpetic Neuralgia (PHN), which is nerve pain that can follow shingles.


Q: Is Gabapentin Aurobindo the same kind of medicine as aspirin or ibuprofen?

No. Gabapentin Aurobindo is chemically classified as an anticonvulsant used to stabilize overactive nerve function in the central nervous system. It works differently than NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) like aspirin or ibuprofen, which primarily reduce pain through anti-inflammatory effects.


Q: Are there different forms or strengths of Gabapentin Aurobindo?

The active ingredient gabapentin is manufactured for oral administration in multiple dosage formats. These generally include hard capsules (e.g., 100 mg, 300 mg, 400 mg), tablets (e.g., 600 mg, 800 mg), and an oral solution.


Q: Is Gabapentin Aurobindo commonly taken long-term?

Gabapentin is prescribed for chronic conditions, such as epilepsy and certain types of chronic nerve pain, which often require extended treatment. Clinical studies for nerve pain typically evaluated use for several weeks, and the total length of therapy is generally determined by the condition being managed, with some uses, like epilepsy, often requiring ongoing treatment.


Q: Does Gabapentin Aurobindo interact with common pain relievers?

Official information indicates that gabapentin is not significantly metabolized by the liver's main enzyme system (CYP450). This suggests a low potential for drug-drug interactions with many common non-narcotic pain relievers. It is important to note that caution is generally recommended when combining gabapentin with any other medicine known to cause drowsiness or sedation.


Q: Does Gabapentin Aurobindo contain any gluten or common allergens?

Specific details about non-active ingredients, or excipients, including potential allergens like lactose, gluten, or certain dyes, are detailed in the official prescribing information for each dosage form. The official documentation allows individuals to check for substances relevant to their sensitivities.


Q: Is Gabapentin Aurobindo a controlled substance in the US?

Gabapentin is currently classified as a non-controlled substance at the federal level by the US Drug Enforcement Administration (DEA). However, several US states have separately classified it as a Schedule V controlled substance.


Q: Are there any specific foods or drinks to avoid while taking Gabapentin Aurobindo?

Official labeling states that gabapentin can be taken with or without food. There are no specific foods or non-alcoholic drinks that regulatory documents recommend must be strictly avoided, noting that administration of antacids containing aluminum or magnesium must be timed separately from gabapentin.


Q: Can Gabapentin Aurobindo affect your mood?

Potential adverse reactions listed in the official safety profile include changes in mood, such as hostility, confusion, emotional lability, and depression. Regulatory bodies also mandate warnings about the rare but serious risk of Suicidal Ideation and Behavior associated with anti-epileptic drugs.


Q: Is it possible for Gabapentin Aurobindo to affect balance or coordination?

Yes, impaired coordination, known as Ataxia, is listed as a very common adverse reaction in the official safety profile. Other very common effects like dizziness and somnolence (drowsiness) can also potentially impact balance.


Q: Can Gabapentin Aurobindo affect the results of any lab tests?

Official prescribing information notes that gabapentin has been associated with some instances of false positive results when specific semi-quantitative protein assays are used to test for urinary protein.


Q: What does official guidance say about driving while taking Gabapentin Aurobindo?

Due to the risk of dizziness, somnolence (drowsiness), and impaired coordination, regulatory guidance advises caution. Official guidance indicates that due to these risks, individuals should assess their reaction to the medicine before driving or operating complex machinery.


Q: Do children experience different side effects from Gabapentin Aurobindo than adults?

Yes. The official safety profile includes specific data for pediatric patients (ages 3 to 12). This group may experience some common reactions not typically seen in adults, such as viral infection, hostility, emotional lability, and hyperkinesia (overactivity).


Q: What is the general duration of treatment with Gabapentin Aurobindo for nerve pain?

The clinical studies that demonstrated the medicine's use for Postherpetic Neuralgia (PHN) typically involved a treatment period of 5 to 8 weeks of active use. The total length of therapy is specific to the patient’s condition and response.


Q: What are the common reasons someone might need to stop taking Gabapentin Aurobindo?

Data from clinical trials indicates that the most common reasons patients discontinued the medicine were due to adverse reactions. These frequently included dizziness, somnolence (drowsiness), and ataxia (impaired coordination).


Q: Are there any specific monitoring or check-ups recommended while using Gabapentin Aurobindo?

Regulatory information advises monitoring for signs of serious adverse reactions, such as DRESS or suicidal ideation, particularly at the start of treatment. Periodic assessment of renal function may be appropriate to determine if dose adjustments are required.


Q: What is the relationship between Gabapentin Aurobindo and depression?

Depression is listed as a potential adverse reaction in the official safety profile. Additionally, regulatory warnings highlight the rare but serious risk of Suicidal Ideation and Behavior that has been associated with anti-epileptic medicines.


Q: What are the known drug-drug interactions listed in the prescribing information for Gabapentin Aurobindo?

Official prescribing information lists documented interactions with several substances. These include opioids (due to the risk of respiratory depression), antacids containing aluminum/magnesium (which reduce gabapentin absorption), and cimetidine (which can cause a minor increase in gabapentin levels).

How should Gabapentin Aurobindo be stored and disposed of?

How to Store and Dispose of Gabapentin (Aurobindo)

Gabapentin formulations must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The medicine must be dispensed and maintained in a tight, child-resistant container and must always be stored out of the reach of children, as required by official labeling.

Stability and Discarding Rules

For scored Gabapentin tablets, any unused half-tablets must be discarded if they are not used within 28 days of the tablet being broken.

Official Disposal Instructions

To dispose of unused or expired medicine, patients should consult a pharmacist or local waste disposal company for guidance. If a take-back program is unavailable, the official guidance recommends mixing the unused product with an undesirable substance (such as dirt) and placing the mixture in a sealed container for trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gabapentin Aurobindo found in:

A-Z Index: